DE60024480D1 - Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika - Google Patents

Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika

Info

Publication number
DE60024480D1
DE60024480D1 DE60024480T DE60024480T DE60024480D1 DE 60024480 D1 DE60024480 D1 DE 60024480D1 DE 60024480 T DE60024480 T DE 60024480T DE 60024480 T DE60024480 T DE 60024480T DE 60024480 D1 DE60024480 D1 DE 60024480D1
Authority
DE
Germany
Prior art keywords
thiazol
imidazo
pharmaceuticals
pyridine compounds
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60024480T
Other languages
English (en)
Other versions
DE60024480T2 (de
Inventor
Laszlo Revesz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9925441.9A external-priority patent/GB9925441D0/en
Priority claimed from GBGB9926173.7A external-priority patent/GB9926173D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE60024480D1 publication Critical patent/DE60024480D1/de
Application granted granted Critical
Publication of DE60024480T2 publication Critical patent/DE60024480T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60024480T 1999-10-27 2000-10-25 Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika Expired - Lifetime DE60024480T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9925441.9A GB9925441D0 (en) 1999-10-27 1999-10-27 Organic compounds
GB9925441 1999-10-27
GBGB9926173.7A GB9926173D0 (en) 1999-11-04 1999-11-04 Organic compounds
GB9926173 1999-11-04
PCT/EP2000/010528 WO2001030778A1 (en) 1999-10-27 2000-10-25 Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use

Publications (2)

Publication Number Publication Date
DE60024480D1 true DE60024480D1 (de) 2006-01-05
DE60024480T2 DE60024480T2 (de) 2006-07-27

Family

ID=26316029

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024480T Expired - Lifetime DE60024480T2 (de) 1999-10-27 2000-10-25 Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika

Country Status (11)

Country Link
US (2) US6608072B1 (de)
EP (1) EP1224185B1 (de)
JP (1) JP2003512467A (de)
AR (1) AR029011A1 (de)
AT (1) ATE311385T1 (de)
AU (1) AU7922900A (de)
CO (1) CO5251463A1 (de)
DE (1) DE60024480T2 (de)
ES (1) ES2254238T3 (de)
PE (1) PE20011039A1 (de)
WO (1) WO2001030778A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
DE69932828T2 (de) 1998-08-29 2007-10-18 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
EP1294718A2 (de) 2000-06-14 2003-03-26 Warner-Lambert Company Llc 6,5-kondensierte bizyklische heterozyklen
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
WO2002062792A1 (fr) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
KR100922538B1 (ko) 2001-08-13 2009-10-21 얀센 파마슈티카 엔.브이. 2,4,5-삼치환된 티아졸릴 유도체 및 그의 항염증성 활성
KR100980163B1 (ko) 2002-01-07 2010-09-03 에자이 알앤드디 매니지먼트 가부시키가이샤 데아자퓨린 및 이의 용도
TWI322807B (en) * 2002-01-07 2010-04-01 Eisai R&D Man Co Ltd Novel deazapurines and uses thereof
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003247959B2 (en) * 2002-07-09 2010-07-29 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
US20040033222A1 (en) * 2002-08-14 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
ATE481402T1 (de) 2003-02-27 2010-10-15 Palau Pharma Sa Pyrazolopyridin-derivate
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TWI334868B (en) * 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
EP1648887A1 (de) * 2003-07-30 2006-04-26 Cyclacel Limited Pyridinylamin-pyrimidin derivate als protein kinase hemmer
US7632950B2 (en) * 2003-08-18 2009-12-15 Fujifilm Finechemicals Co., Ltd Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them
GB0401336D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7504403B2 (en) * 2004-01-22 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
EP1810972B1 (de) * 2004-11-10 2012-01-25 Ono Pharmaceutical Co., Ltd. Stickstoffhaltige heterocyclische verbindung und deren pharmazeutische verwendung
KR100848205B1 (ko) * 2005-06-20 2008-07-24 주식회사 동부하이텍 면역 억제 및 염증 억제 활성을 갖는 신규한 치환된1,3-티아졸 유도체 또는 이의 약학적으로 허용가능한 염,중간체 화합물 또는 이의 약학적으로 허용가능한 염, 이의제조방법, 및 이를 포함하는 약학적 조성물
WO2007034278A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Fused imidazole derivatives as c3a receptor antagonists
CN101277956A (zh) 2005-09-30 2008-10-01 阿斯利康(瑞典)有限公司 具有抗细胞增殖活性的咪唑并【1，2-a】吡啶
EP1932840B1 (de) 2005-10-03 2014-04-09 Ono Pharmaceutical Co., Ltd. Stickstoffhaltige heterocyclische verbindung und pharmazeutische anwendung davon
CA2698075C (en) * 2007-08-27 2016-04-12 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
WO2009076140A1 (en) * 2007-12-13 2009-06-18 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
ES2548135T3 (es) * 2008-05-13 2015-10-14 Novartis Ag Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa
CN105001196B (zh) * 2008-12-03 2017-05-10 斯克里普斯研究所 干细胞培养
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
NZ596123A (en) * 2009-05-19 2014-08-29 Dow Agrosciences Llc Compounds and methods for controlling fungi
WO2012116145A1 (en) * 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
CN103145706B (zh) * 2012-11-16 2015-11-25 温州医学院 一类具有抗炎作用的咪唑并吡啶类化合物及其在制备抗炎药物中的应用
TWI623531B (zh) 2012-11-21 2018-05-11 Ｐｔｃ治療公司 經取代反向嘧啶ｂｍｉ－１抑制劑
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
KR102232595B1 (ko) 2013-08-30 2021-03-26 피티씨 테라퓨틱스, 인크. 치환된 피리미딘 bmi-1 저해제
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
GB201321739D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
RS63190B1 (sr) 2014-08-04 2022-06-30 Nuevolution As Opciono fuzionisani derivati pirimidina zamenjeni heterociklilom korisni za lečenje zapaljenskih, metaboličkih, onkoloških i autoimunskih bolesti
AU2016233289A1 (en) * 2015-03-18 2017-11-09 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of TNF
KR102654709B1 (ko) * 2015-03-18 2024-04-03 브리스톨-마이어스 스큅 컴퍼니 치환된 트리시클릭 헤테로시클릭 화합물
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
WO2019142128A1 (en) * 2018-01-18 2019-07-25 Integral Biosciences Private Limited Dual inhibitors of alk5 and p38α map kinase
MX2021001870A (es) 2018-08-17 2021-07-15 Ptc Therapeutics Inc Metodo para tratar cancer pancreatico.
HRP20240401T1 (hr) 2018-10-05 2024-06-07 Annapurna Bio Inc. Spojevi i pripravci za liječenje patoloških stanja koja su povezana s djelovanjem apj receptora
EP4076657A1 (de) 2019-12-20 2022-10-26 Nuevolution A/S Gegen nukleäre rezeptoren wirksame verbindungen
EP4126875A1 (de) 2020-03-31 2023-02-08 Nuevolution A/S Gegen nukleare rezeptoren aktive verbindungen
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6058981A (ja) * 1983-09-09 1985-04-05 Takeda Chem Ind Ltd ５−ピリジル−１，３−チアゾ−ル誘導体，その製造法およびそれを含んでなる医薬組成物
JP3264492B2 (ja) * 1992-01-13 2002-03-11 スミスクライン・ビーチャム・コーポレイション ピリジル置換イミダゾール
WO1995013067A1 (en) * 1993-11-08 1995-05-18 Smithkline Beecham Corporation Oxazoles for treating cytokine mediated diseases
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
WO1997005878A1 (en) 1995-08-10 1997-02-20 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
DE69728688T2 (de) * 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
ZA9711092B (en) * 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
AU7132998A (en) * 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
TR200001079T2 (tr) * 1997-10-20 2000-07-21 F.Hoffmann-La Roche Ag Bisiklik kinaz inhibitörleri.
WO1999021555A2 (en) * 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
JP3990061B2 (ja) * 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
AU4506399A (en) * 1998-06-05 1999-12-30 Novartis Ag Aryl pyridinyl thiazoles
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
CO5170501A1 (es) * 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
JP3333774B2 (ja) * 1999-04-23 2002-10-15 武田薬品工業株式会社 ５−ピリジル−１，３−アゾール化合物、その製造法及び用途
US7101899B1 (en) * 1999-04-23 2006-09-05 Takeda Pharmaceutical Company Limited 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
US6492516B1 (en) 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity

Also Published As

Publication number Publication date
US6608072B1 (en) 2003-08-19
ES2254238T3 (es) 2006-06-16
ATE311385T1 (de) 2005-12-15
WO2001030778A1 (en) 2001-05-03
PE20011039A1 (es) 2001-10-30
US6891039B2 (en) 2005-05-10
US20040082604A1 (en) 2004-04-29
DE60024480T2 (de) 2006-07-27
CO5251463A1 (es) 2003-02-28
AR029011A1 (es) 2003-06-04
EP1224185B1 (de) 2005-11-30
EP1224185A1 (de) 2002-07-24
AU7922900A (en) 2001-05-08
JP2003512467A (ja) 2003-04-02

Similar Documents

Publication Publication Date Title
DE60024480D1 (de) Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika
DE60202200D1 (de) Imidazo[1,2-a]-pyridinderivate als mglur5 antagonisten
EE200200080A (et) Imidaso[1,2a]püridiini ja pürasolo[2,3a]püridiiniderivaadid
DE60014603D1 (de) Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
DK1470124T3 (da) 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
DE60021262D1 (de) Bizyklische heteroaromatische verbindungen als lh-agonisten
DK1147112T3 (da) Diazabicykliske derivater som nicotiniske acetylcholinreceptorligander
ATE375987T1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DK1163227T3 (da) Bicykliske heterocykliske forbindelser, farmaceutiske præparater indeholdende disse forbindelser og fremgangsmåder til fremstilling deraf
ATE299503T1 (de) Pyridin-3-carbonsäurederivate und ihre verwendung als zwischenprodukte
DE60332396D1 (de) PYRAZOLOi3,4-B PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PHOSPHODIESTERASE INHIBITOREN
NO20013419L (no) Substituerte 2-aryl-3-(heteroaryl)-imidazo[1,2a]pyrimidiner, med dertil horende farmasoytiske preparater samt metoder.
DE60034683D1 (de) 3(5)-ureido-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
DE60023012D1 (de) 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
DE50008597D1 (de) Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
ATE309247T1 (de) Heteroaryl substituierte 2-pyridinyl und 2- pyrimidinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-onderivate
AU2003255323A8 (en) Imidazo`1,2-a pyridines
NO20013384D0 (no) Imidazo[4,5-c]pyridin-4-on-derivater
ATE264315T1 (de) Aminothiazolderivate und ihre verwendung als crf- rezeptor-liganden
ATE260259T1 (de) Substituierte isochinolinderivate und ihre verwendung als anticonvulsiva
EE04372B1 (et) 5-asendatud-3-oksadiasolüül-1,6-naftüridiin-2(1H)-ooni derivaadid
DE60005349D1 (de) Dithiepino[6,5-b]pyridine und diese verwendete zusamensetzungen und methode
NO20031412L (no) Substituerte 3,4-dihydro-pyrido[1,2-A]pyrimidiner
DK1326866T3 (da) Substituerede 3,4-dihydro-pyrido[1,2-a]pyrimidiner

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN